Clinical trials recruiting in Waratah, Australia

Phase breakdown

Conditions recruiting in Waratah, Australia

Recruiting trials in Waratah, Australia

• A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
  NCT07623369 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
  NCT07365319 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
  NCT05920356 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of AZD0120 in Autoimmune Diseases
  NCT07295847 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
  NCT06914128 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  NCT06623422 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
  NCT04913285 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  NCT07144280 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
  NCT07535112 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
  NCT06452277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
  NCT07224373 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female)
• Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
  NCT03340129 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female)
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07562152 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
  NCT06756932 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Duration of Anti-PD-1 Therapy in Metastatic Melanoma
  NCT02821013 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
  NCT07262619 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Implementing Surgery School Prehabilitation Using Telehealth
  NCT06631872 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
  NCT06712355 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
  NCT07334119 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
  NCT05180942 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female)
• Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
  NCT07140900 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male
• Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
  NCT06881784 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
  NCT04429542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
  NCT06598306 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
  NCT07565285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Waratah, Australia?

34 recruiting trials have at least one study site in Waratah, Australia.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.